Carling Communications Inc. announced that Sherri Wilkins has been named the agency’s Chief Creative Officer.
Amgen Inc. said its potent new cholesterol fighter Repatha met the primary and secondary goals of a study designed to show it can decrease plaque buildup in heart arteries of patients already taking widely used statin drugs, such as Lipitor.
Pfizer will exit a site in upstate New York it has operated since 2011. The company expects to shutter the facility in early 2018, displacing about 120 employees, the Press Republican reported.
In yet another buy in its string of acquisitions, Dublin-based Allergan announced it was acquiring San Francisco-based Tobira Therapeutics.
GlaxoSmithKline said it had chosen its head of consumer healthcare, Emma Walmsley, as its new chief executive after several months of reviewing candidates.
Teva Pharmaceutical Industries is banking big time on New York-based Regeneron’s investigational NGF antibody, fasinumab, for the treatment of osteoarthritis pain and low back pain.
German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.
A new “flash” blood sugar monitoring system cuts down on episodes of low blood sugar in people with type 1 diabetes, researchers say.
Sarepta Therapeutics Inc.’s Duchenne muscular dystrophy drug won approval from the U.S. FDA, capping months of regulatory uncertainty.
The U.S. Food and Drug Administration approved Bayer AG’s hormonal contraceptive device Kyleena to prevent pregnancy for up to five years.
Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.
Johnson & Johnson has indicated that its acute myeloid leukemia (AML) drug, JNJ-63709178, has been put on clinical hold because of serious side effects.
Japan’s Astellas Pharma Inc. and San Diego-based Vical Inc. said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.
A global fund has raised over $12.9 billion from international donors as part of a campaign aimed at effectively eradicating AIDS, malaria and tuberculosis by 2030, conference organizers said.
Novartis’ investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said, citing a new analysis of a late-stage trial.
Johnson & Johnson announced it will acquire Abbott Medical Optics for more than $4 billion. The deal is expected to close in the first quarter of 2017.
The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported.
Brain cancer is now the deadliest form of childhood cancer in the United States, surpassing leukemia as treatment advances have allowed doctors to cure many blood-related cancers, the Centers for Disease Control and Prevention said.
U.S. drugmaker Pfizer Inc.’s breast cancer drug Ibrance should be given marketing approval, an advisory committee at the European Medicines Agency recommended.
AstraZeneca said combining its Forxiga diabetes drug with Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own.